FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences:
To access the live webcast and archived recordings of the fireside chats, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recordings will be available for 90 days following each event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2023 Phathom Pharmaceuticals. All rights reserved.
DENVER, CO / ACCESSWIRE / March 22, 2024 / (OTC Pink:YUKA) Med Holdings Group, Inc.…
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…
Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…
Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…
The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…